Social media

Open claims datasets are one of the most powerful tools in healthcare analytics—offering broad coverage and timely insights that help life sciences organisations stay ahead. Yes, disruptions can happen. With the right...

Open-sourced claims data: powerful, timely, essential—and sometimes disruptive. Open claims datasets offer unmatched breadth of coverage and speed of insight, making them a vital tool for life sciences organisations. Ye...

Are you going to CPHI? If so come along to our VIP in-person event on Tuesday 28th October where our panel of industry experts will discuss the challenges around accelerating timelines and reducing costs in early clinica...

Reach clinical trial participants faster. Our integrated oncology solutions reduce barriers, enhance engagement, and boost recruitment and retention. https://ow.ly/czVv50X8WST

Visit the ICON team at #ACR25, booth 1501 to discover how our strategic solutions and innovative methods help reduce patient burden, meet enrolment targets, and accelerate access to new treatment options for autoimmune d...

Systemic autoimmune rheumatic diseases are rising globally. Speak with ICON experts at #ACR25, booth \#1501 to learn how our deep experience delivering rheumatology studies helps sponsors to advance autoimmune therapie...

As oncology biologics face expiring patents, biosimilar developers need to prepare for a new era of opportunity and market growth. In this article, ICON’s Kim Salgado examines the opportunities and regulatory shifts th...

For AI biomarker discovery in oncology to move forward, developers must address several challenges. Find out what these are, and why AI is still positioned to transform the landscape of oncology therapeutics, in the arti...

AI can find patterns in large datasets and detect complex relationships in patient data — making it a key tool for finding relevant oncology biomarkers. Read the article to discover how AI is being used in oncology bio...

Automation offers new opportunities to increase efficiency and reduce costs associated with post-marketing pharmacovigilance. Yet with patient safety at stake, the adoption of new technologies requires careful assessment...

The FDA and other health authorities like the EMA require a well-defined and consistent drug development process and life cycle management plan. CMC is a critical and a ‘first step’ component in the creation of a develop...

Upstream and downstream process, structural characterisation, functional characterisation and processes are all major CMC related steps that need to be considered by emerging and biotech companies early in their developm...